DK1521600T3 - Bisacyloxypropylcystein-konjugat og anvendelse heraf - Google Patents

Bisacyloxypropylcystein-konjugat og anvendelse heraf

Info

Publication number
DK1521600T3
DK1521600T3 DK03765055T DK03765055T DK1521600T3 DK 1521600 T3 DK1521600 T3 DK 1521600T3 DK 03765055 T DK03765055 T DK 03765055T DK 03765055 T DK03765055 T DK 03765055T DK 1521600 T3 DK1521600 T3 DK 1521600T3
Authority
DK
Denmark
Prior art keywords
formula
ooc
coo
polyoxyethylene
new
Prior art date
Application number
DK03765055T
Other languages
Danish (da)
English (en)
Inventor
Michael Morr
Peter Muehlradt
Original Assignee
Helmholtz Infektionsforschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Infektionsforschung filed Critical Helmholtz Infektionsforschung
Application granted granted Critical
Publication of DK1521600T3 publication Critical patent/DK1521600T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK03765055T 2002-07-19 2003-07-18 Bisacyloxypropylcystein-konjugat og anvendelse heraf DK1521600T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016066A EP1382352A1 (de) 2002-07-19 2002-07-19 Bisacyloxypropylcystein-Konjugate und deren Verwendung
PCT/EP2003/007892 WO2004009125A2 (de) 2002-07-19 2003-07-18 Bisacyloxypropylcystein-konjugate und deren verwendung

Publications (1)

Publication Number Publication Date
DK1521600T3 true DK1521600T3 (da) 2008-06-09

Family

ID=29762661

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03765055T DK1521600T3 (da) 2002-07-19 2003-07-18 Bisacyloxypropylcystein-konjugat og anvendelse heraf

Country Status (13)

Country Link
US (1) US7316996B2 (sl)
EP (3) EP1382352A1 (sl)
AT (1) ATE385422T1 (sl)
AU (1) AU2003251002B2 (sl)
CA (1) CA2489010C (sl)
CY (1) CY1107929T1 (sl)
DE (1) DE50309128D1 (sl)
DK (1) DK1521600T3 (sl)
ES (1) ES2301832T3 (sl)
HK (1) HK1074802A1 (sl)
PT (1) PT1521600E (sl)
SI (1) SI1521600T1 (sl)
WO (1) WO2004009125A2 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19652586A1 (de) * 1996-12-17 1998-06-18 Biotechnolog Forschung Gmbh Dhc-Peptid und Mittel
WO2003028358A2 (en) 2001-09-24 2003-04-03 Nice Systems Ltd. System and method for the automatic control of video frame rate
EP1484064A1 (en) * 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
EP1776963A1 (en) 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
EP1787660A1 (en) * 2005-11-22 2007-05-23 GBF Gesellschaft für Biotechnologische Forschung mbH New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions
EP1897557A1 (en) 2006-09-07 2008-03-12 Helmholtz-Zentrum für Infektionsforschung GmbH Use of glycolipids as adjuvants
DE102006045453A1 (de) * 2006-09-26 2008-04-03 Khs Ag Transportsystem
EP2196196A1 (en) * 2008-12-10 2010-06-16 Medipol S.A. Compound, medicament, vaccine composition and nanocapsules
EP2305283A1 (en) * 2009-09-24 2011-04-06 Helmholtz-Zentrum für Infektionsforschung GmbH Pharmaceutical compositions for treating dysregulated inflammatory diseases
EP2338521A1 (en) * 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
EA023725B1 (ru) * 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
JP2013537892A (ja) 2010-09-22 2013-10-07 ザ ユニバーシティー オブ メルボルン 新規な免疫賦活法
MX2013003451A (es) * 2010-09-30 2013-09-02 Franvax S R L Generacion de particulas de virosoma.
EP2522350B1 (de) 2011-05-12 2013-07-31 Immunopharm AG Verwendung der Wirkstoffkombination aus einem 1-Diethylaminoethyl-3-Chinoxalin-2-on Derivat und einem Oxysterol zur Durchbrechung von Resistenzen bei der Behandlung von Krebs und zur Erhöhung der Immunleistungsfähigkeit bei Krebs, bakteriellen und viralen Erkrankungen, Autoimmunerkrankungen, erhöhter Stress- und Umweltbelastung
EP3087054A4 (en) 2013-12-27 2017-10-25 Novus International Inc. Ethoxylated surfactants
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
CN115501125A (zh) * 2022-10-20 2022-12-23 澳门科技大学 用于修复皮肤损伤的h2s供体凝胶及h2s供体凝胶制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
AU666789B2 (en) * 1992-12-28 1996-02-22 Takeda Chemical Industries Ltd. 2-amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof
EP0604945A1 (en) * 1992-12-28 1994-07-06 Takeda Chemical Industries, Ltd. TAN-1511, its derivatives, production and use thereof
CA2128552A1 (en) * 1993-07-22 1995-01-23 Hida Tsuneaki Derivatives of 6,7-dihydroxy-4-thiaheptanoic acid and their use
DE19652586A1 (de) * 1996-12-17 1998-06-18 Biotechnolog Forschung Gmbh Dhc-Peptid und Mittel
EP2305804B1 (en) * 1999-01-14 2015-05-06 Bolder Biotechnology, Inc. MonoPEGylated human growth hormone

Also Published As

Publication number Publication date
AU2003251002B2 (en) 2009-02-26
CA2489010A1 (en) 2004-01-29
ATE385422T1 (de) 2008-02-15
CY1107929T1 (el) 2013-09-04
US20060134061A1 (en) 2006-06-22
EP1521600A2 (de) 2005-04-13
WO2004009125A2 (de) 2004-01-29
EP1521600B1 (de) 2008-02-06
HK1074802A1 (en) 2005-11-25
AU2003251002A1 (en) 2004-02-09
US7316996B2 (en) 2008-01-08
DE50309128D1 (de) 2008-03-20
WO2004009125A3 (de) 2004-05-27
PT1521600E (pt) 2008-05-13
EP1382352A1 (de) 2004-01-21
CA2489010C (en) 2012-01-17
EP1955713A1 (de) 2008-08-13
SI1521600T1 (sl) 2008-08-31
ES2301832T3 (es) 2008-07-01

Similar Documents

Publication Publication Date Title
HK1074802A1 (en) Bisacyloxypropylcysteine conjugates and the use thereof
CA2063886A1 (en) Polyethylene protein conjugates
DK2158923T3 (da) Peg-uratoxidase-konjugater og anvendelse deraf
WO2006059029A3 (fr) Solutions viscoelastiques renfermant du hyaluronate de sodium et de l'hydroxypropylmethyl- cellulose, preparation et utilisations
CA2203480A1 (en) Interferon conjugates
HRP20070432A2 (en) Gastroresistant pharmaceutical formulations containing rifaximin
WO2005028539A3 (en) Multi-arm polymer prodrugs
EP2626368A3 (en) Insulin-oligomer conjugates, formulations and uses thereof
WO2000064486A3 (en) Enzymatically activated polymeric drug conjugates
HUP0103003A2 (hu) PEG/karbamát oxidáz konjugátumok és alkalmazásuk
WO1990015628A1 (en) Polymer/antibiotic conjugate
WO2006119029A3 (en) Ball pitching machine
AU2002215904A1 (en) Compounds with a branched linker
AU1373197A (en) Covalent lipid-phosphonocarboxylic acid conjugates, the production thereof as well as their use as antiviral pharmaceutical agents
HRP20040303B1 (en) Use of specific dose of fondaparinux sodium for the treatment of acs
TWI266801B (en) Polyol-IFN-beta conjugates
CY1114005T1 (el) Συζευγματα peg-ουρικης οξειδασης και χρηση αυτων